A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Buparlisib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Basalt-3
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 16 Mar 2017 This trial has been completed in UK (End date:2015-08-04) as per European Clinical Trials Database record.
- 16 Nov 2016 Status changed from completed to discontinued as review of safety and preliminary efficacy data showed marginal anti-tumor activity.